Fresh Frozen Plasma Dose Calculator

The Fresh Frozen Plasma (FFP) Dose Calculator determines the appropriate volume and number of FFP units needed for a patient based on weight and the desired dosing intensity. FFP contains all coagulation factors, fibrinogen, natural anticoagulants, and other plasma proteins, making it essential for correcting complex coagulopathies, warfarin reversal when prothrombin complex concentrate is unavailable, massive transfusion, and specific factor deficiencies when specific factor concentrates are not available.

Standard FFP dosing ranges from 10-20 mL/kg, with 10-15 mL/kg being the most commonly used initial dose. This dose typically increases coagulation factor levels by 15-25%, which is usually sufficient to achieve hemostatic levels (approximately 30% of normal for most factors). Higher doses (15-20 mL/kg) may be needed for severe coagulopathy, DIC, or when the INR is markedly elevated. Each FFP unit contains approximately 200-250 mL of plasma and delivers approximately 1 unit/mL of each coagulation factor.

The indications for FFP transfusion should be evidence-based, as inappropriate FFP use is a significant healthcare quality issue. Accepted indications include: active bleeding with documented coagulopathy (elevated PT/INR or aPTT), massive transfusion protocol (typically 1:1:1 ratio with RBCs and platelets), urgent warfarin reversal when 4-factor PCC is unavailable, DIC with active bleeding, liver disease with coagulopathy and bleeding or before procedures, thrombotic thrombocytopenic purpura (TTP) for plasma exchange, and replacement of specific factor deficiencies when concentrates are unavailable.

FFP should NOT be used for volume expansion (albumin or crystalloid are appropriate), for nutritional support, to correct mildly elevated INR in non-bleeding patients, or prophylactically before minor procedures in patients with minimally prolonged coagulation times. Studies have shown that FFP is frequently transfused inappropriately, with up to 30-50% of transfusions not meeting established criteria. Each unnecessary transfusion exposes patients to risks without benefit and wastes a limited resource.

The relationship between FFP dose and INR correction is non-linear. For INR values between 2.0 and 3.0, a dose of 10-15 mL/kg typically reduces the INR to below 1.5. However, for INR values above 5.0, larger doses (15-20 mL/kg) may be needed, and complete normalization may not be achievable with FFP alone due to dilutional constraints. Prothrombin complex concentrates (PCCs), which provide concentrated vitamin K-dependent factors in a small volume, are more effective for rapid INR reversal and are now preferred over FFP for warfarin reversal in many guidelines.

Administration considerations include ABO compatibility (FFP must be ABO-compatible with the recipient), thawing time (approximately 30 minutes from frozen, which may delay administration in emergencies), and transfusion rate (typically 10-20 mL/min in adults, slower in patients at risk for volume overload). Thawed plasma must be transfused within 24 hours (or within 5 days if relabeled as thawed plasma). Transfusion risks include allergic reactions (most common, 1-3%), TRALI (serious but rare), volume overload (particularly in cardiac or renal patients), and citrate toxicity with rapid or massive transfusion.